3987-92-6

Usage

Uses

Used in Scientific Research:
METHYL 4-AMINO-3-NITROBENZOATE is used as a starting material for the synthesis of various compounds, contributing to the advancement of chemical research and development.
Used in Chemical Synthesis Industry:
METHYL 4-AMINO-3-NITROBENZOATE is used as a precursor in the production of other chemical compounds, playing a crucial role in the synthesis process and enabling the creation of new materials and products.

InChI:InChI=1/C8H8N2O4/c1-14-8(11)5-2-3-6(9)7(4-5)10(12)13/h2-4H,9H2,1H3

Upstream product

• 1588-83-6 4-amino-3-nitrobenzoic acid 
• 53178-59-9 methyl benzofuroxan-5-carboxylate 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 619-45-4 4-methoxycarbonyl aniline 
• 618-95-1 methyl 3-nitrobenzoate 
• 118535-52-7 N,N-tetramethylene-thiocarbamoyl-sulphenamide 
• 865-47-4 potassium tert-butylate 
• 67-56-1 methanol 

Downstream Products

• 36692-49-6 Methyl 3,4-diaminobenzoate 
• 928850-32-2 methyl 3-nitro-4-[(phenylacetyl)amino]benzoate 
• 68502-46-5 4-benzylamine-3-nitro-benzoic acid methyl ester 
• 172221-28-2 methyl 4-amino-3-iodo-5-nitro-benzoate 
• 35532-08-2 2-(4-carboxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid 
• 110336-03-3 2-(4-methoxycarbonyl-phenyl)-1⁽³⁾H-benzimidazole-5-carboxylic acid methyl ester 
• 327046-64-0 methyl 4-[(tert-butoxy)carbonylamino]-3-nitrobenzoate 
• 1072139-13-9 methyl 4-[N-(2-methyl-1-propen-1-yl)amino]-3-nitrobenzoate 
• 36242-50-9 4-methylamino-3-nitro-benzoic acid methyl ester 
• 1381944-43-9 methyl 3-nitro-4-((2-ethoxy-2-oxoethyl) amino)benzoate 
• 113053-50-2 1H-Benzotriazole-5-carboxylic acid methyl ester 
• 73605-91-1 1H-benzotriazole-5-carboxylic acid ethyl ester 
• 23814-12-2 1h-benzotriazole-5-carboxylic acid 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation: 5-amino-1h-pyrazole-1-carbonyl derivatives as fgfr inhibitors

Background: Fibroblast growth factors (FGFs) and their high affinity receptors (FGFRs) play a major role in cell proliferation, differentiation, migration, and apoptosis. Aberrant FGFR signaling pathway might accelerate development in a broad panel of mal

Preparation method of 3-acetylindole BRPF1 inhibitor and use of 3-acetylindole BRPF1 inhibitor

The invention relates to a 3-acetylindole compound of a novel structure shown in a formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate or a solvate thereof, a preparation method of the compound, a pharmaceutical composition containing a therapeutically effective dose of the compound, and use thereof as a protein tyrosine kinase inhibitor, especially as a bromine-containing area PHD zinc finger protein 1 (BRPF1) inhibitor, in the prevention or treatment of disease benefited from the inhibition of BRPF1.

Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors

Fe(II)/α-ketoglutarate-dependent lysine demethylases (KDMs) are attractive drug targets for several diseases including cancer. In this study, we designed and screened ortho-substituted anilides that are expected to function as Fe(II) chelators, and identified ortho-hydroxy anilide as a novel scaffold for KDM5A inhibitors. Treatment of human lung cancer A549 cells with a prodrug form of 4-carboxy-2-hydroxy-formanilide (9c) increased trimethylated lysine 4 on histone H3 level, suggesting KDM5 inhibition in the cells.

1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation

Glycogen synthase kinase 3 (GSK-3)has become known for its multifactorial involvement in the pathogenesis of Alzheimer's disease. In this study, a benzothiazole- and benzimidazole set of 1-aryl-3-(4-methoxybenzyl)ureas were synthesised as proposed Cys199-targeted covalent inhibitors of GSK-3β, through the incorporation of an electrophilic warhead onto their ring scaffolds. The nitrile-substituted benzimidazolylurea 2b (IC50 = 0.086 ± 0.023 μM)and halomethylketone-substituted benzimidazolylurea 9b (IC50 = 0.13 ± 0.060 μM)displayed high GSK-3β inhibitory activity, in comparison to reference inhibitor AR-A014418 (1, IC50 = 0.072 ± 0.043)in our assay. The results suggest further investigation of 2b and 9b as potential covalent inhibitors of GSK-3β, since a targeted interaction might provide improved kinase-selectivity.

Synthesis and biological evaluation of N-substituted 3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxylic acid derivatives as tubulin polymerization inhibitors

A series of novel N-substituted 3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxy- lic acid derivatives were synthesized and evaluated for their biological activities. Among all synthesized target compounds, 13d exhibited the most potent antiproliferative ac

The discovery of new scaffold of plant activators: From salicylic acid to benzotriazole

Started from salicylic acid (SA) and related commercialized plant activators, based on molecular three-dimensional shape and pharmacophore similarity comparison (SHAFTS), a new lead compound benzotriazole was predicted and a series of benzotriazole derivatives were designed and synthesized. The bioassay showed that benzotriazole had high activity against a broad spectrum of diseases including fungi and oomycetes in vivo, but no activity in vitro. And the introduction of proper groups at the 1’-position and 5’-position was beneficial to the activity. So, they had the potential to be exploited as novel plant activators.

Nitrogen substitutive 3-oxygen substitutive-6-tetrahydroquinoxaline substitutive structure compound and preparation method and medical application thereof

Disclosed are nitrogen substitutive 3-oxygen substitutive-6-tetrahydroquinoxaline substitutive structure compound and preparation method and medical application thereof. The general structure of the compound is as shown in the formula (I). The compound has tubulin polymerization inhibition activities, and is good in tumor disease resistance and proliferative disease apart from tumors.

PYRIMIDINE FGFR4 INHIBITORS

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit

The synthesis of a novel series of potent chiral inhibitors of histone deacetylase (HDAC) is described that contain a heterocyclic capping group and a N-(2-aminophenyl)benzamide unit that binds in the active site. In vitro assays for the inhibition of HDAC1, HDAC2, HDAC3-NCoR1, and HDAC8 by the N-(2-aminophenyl)benzamide 24a gave respective IC50 values of 930, 85, 12, and 4100 nM, exhibiting class I selectivity and potent inhibition of HDAC3-NCoR1. Both imidazolinone and thiazoline rings are shown to be effective replacements for the pyrimidine ring present in many other 2-(aminophenyl) benzamides previously reported, an example of each ring system at 1 μM causing an increase in histone H3K9 acetylation in the human cell lines Jurkat and HeLa and an increase in cell death consistent with induction of apoptosis. Inhibition of the growth of MCF-7, A549, DU145, and HCT116 cell lines by 24a was observed, with respective IC50 values of 5.4, 5.8, 6.4, and 2.2 mM.

INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.